IF: 1.578
Cite Score:

Drug-Related Mutational Patterns in Hepatitis B Virus (HBV) Reverse Transcriptase Proteins From Iranian Treatment-Naïve Chronic HBV Patients


Mostafa Mahabadi 1 , Mehdi Norouzi 1 , Seyed Moayed Alavian 2 , katayoun samimirad 3 , Talat Mokhtari Azad 1 , Esmaeil Saberfar 4 , Mahmood Mahmoodi 5 , fatemeh ramezani 1 , Hadi Karimzadeh 1 , Reza Malekzadeh 6 , G montazeri 6 , Azim Nejatizadeh 7 , Masood Ziaee 8 , Farshid Abedi 9 , behrooz ataei 10 , Majid Yaran 10 , Babak Sayad 11 , Mohammad Somi 12 , Gholamreza Sarizadeh 13 , Ismaeil Sanei-Moghaddam 14 , Fariborz Mansour-Ghanaei 15 , Houshang Rafatpanah 16 , Mohammad Amin Pourhosseingholi 17 , Hossein Keyvani 18 , Ebrahim Kalantari 19 , Mehdi Saberifiroozi 20 , Mohammad Ali Judaki 1 , Shiva Ghamari 1 , Maryam Daram 1 , Zeinab Fazeli 1 , Zahra Goodarzi 4 , Abulfazl Khedive 1 , Abdolvahab Moradi 21 , Seyed Mohammad Jazayeri 1 , *


1 Hepatitis B Molecular Laboratory, Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, IR Iran

2 Middle East Liver Diseases Center (MELD Centers), Tehran, IR Iran

3 Hepatitis C Molecular Laboratory, Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, IR Iran

4 The research and development department of Bayerpaul vaccine and pharmaceutical company, Tehran, IR Iran

5 Department of Epidemiology, School of Public Health, Tehran University of Medical Sciences, Tehran, IR Iran

6 Digestive Disease Research Center, Tehran University of Medical Sciences, Tehran, IR Iran

7 Research Center for Molecular Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, IR Iran

8 Hepatitis Research Center , Department of Internal Medicine, Faculty of medicine, Birjand University of Medical Sciences, Birjand, IR Iran

9 Department of Infectious Disease, Mashhad University of Medical Sciences, Mashhad, IR Iran

10 Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, IR Iran

11 Kermanshah Liver Diseases and Hepatitis Research Center, Kermanshah, IR Iran

12 Liver and Gastrointestinal Disease Research Center, Tabriz University of Medical Sciences, Tabriz, IR Iran

13 Educational Region of Khouzestan Blood Transfusion Organization, Ahvaz, IR Iran

14 Department of Gastroenterology, Zahedan University of Medical Sciences, Zahedan, IR Iran

15 Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, IR Iran

16 Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, IR Iran

17 Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran

18 Department of Virology, School of Medicine, Tehran University of Medical Sciences, Tehran, IR Iran

19 Gholhack Medical Laboratory, Tehran, IR Iran

20 Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran

21 Department of Microbiology, School of Medicine, Golestan University of Medical Sciences, Gorgan, IR Iran


Hepatitis Monthly: 13 (1); e93042
Published Online: January 20, 2013
Article Type: Research Article
Received: May 06, 2019
Accepted: November 12, 2012




Background: Immunomodulators and Nucleotide analogues have been used globally for the dealing of chronic hepatitis B virus (HBV) infection. However, the development of drug resistance is a major limitation to their long-term effectiveness.

Objectives: The aim of this study was to characterize the hepatitis B virus reverse transcriptase (RT) protein variations among Iranian chronic HBV carriers who did not receive any antiviral treatments.

Materials and Methods: Hepatitis B virus partial RT genes from 325 chronic in active carrier patients were amplified and directly sequenced. Nucleotide/amino acid substitutions were identified compared to the sequences obtained from the database.

Results: All strains belonging to genotype D.365 amino-acid substitutions were found. Mutations related to lamivudine, adefovir, telbivudine, and entecavir occurred in (YMDD) 4% (n = 13), (SVQ) 17.23% (n = 56), (M204I/V + L180M) 2.45% (n = 8) and (M204I) 2.76% (n = 9) of patients, respectively.

Conclusions: RT mutants do occur naturally and could be found in HBV carriers who have never received antiviral therapy. However, mutations related to drug resistance in Iranian treatment-naïve chronic HBV patients were found to be higher than other studies published formerly. Chronic HBV patients should be monitored closely prior the commencement of therapy to achieve the best regimen option.


Therapy Drug-Resistance Hepatitis B Virus Iran

© 2013, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
  • 1. The references are available in the PDF file.